Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
259 studies found for:    MC1R
Show Display Options
Rank Status Study
1 Completed Strength Training Induced Alterations in Markers of Immune Function
Condition: Inflammation
Intervention: Behavioral: Strength Training
2 Completed Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine
Condition: Vulvar Disease
Intervention: Drug: topical lidocaine + oral desipramine, and/or placebo
3 Recruiting Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma
Condition: Melanoma
Intervention:
4 Completed
Has Results
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
5 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
6 Active, not recruiting Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families
Conditions: Preventive Health Services;   Health Promotion
Intervention: Other: Redesigned Well-Child Care
7 Not yet recruiting Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouricil for Rectal Cancer
Conditions: Mucinous Adenocarcinoma of the Rectum;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIA to IIIC Rectal Cancer
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: fluorouracil;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Procedure: therapeutic conventional surgery
8 Completed A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Interventions: Drug: OSI-906;   Other: Placebo
9 Not yet recruiting 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
Conditions: High Risk MC4R Genotype;   Low Risk MC4R Genotype;   One Week or Less Antipsychotic Lifetime Exposure
Interventions: Drug: Ziprasidone;   Drug: aripiprazole, quetiapine, or risperidone
10 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV/r + FTC/TDF
11 Unknown  Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol
Condition: Subsyndromal Delirium
Interventions: Drug: Haloperidol decanoate;   Drug: Placebo
12 Recruiting A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: GM-CSF;   Other: GM-CSF Placebo;   Biological: Placebo
13 Terminated
Has Results
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
Condition: Parkinson Disease
Interventions: Drug: Coenzyme Q10 with vitamin E;   Drug: placebo with vitamin E
14 Recruiting Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo;   Drug: Fulvestrant;   Drug: BKM120
15 Active, not recruiting
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane;   Drug: Placebo, Exemestane
16 Recruiting Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124®);   Drug: Placebo
17 Active, not recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
18 Completed
Has Results
Long-Term, Open Label Atomoxetine Study
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: atomoxetine
19 Enrolling by invitation Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Viaskin Peanut 250 mcg
20 Active, not recruiting A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Condition: Psoriasis
Interventions: Drug: 80mg LY2439821 Dosing Regimen;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years